Relief Therapeutics (OTCQB:RLFTF) announced Friday that its oral experimental therapy RLF-OD032 in a proof-of-concept trial performed at a similar level to Kuvan, a treatment developed by BioMarin Pharmaceutical (NASDAQ:BMRN) for the metabolic disorder phenylketonuria. Based on topline data, the Swiss biotech